Explore / Clinical trial
Clinical trial

Effects of Ketamine and Risperidone on Cognition

University of ManchesterCompletedPhase 4Started Jun 1, 201087 enrolledUnited KingdomNCT01140620

Abstract

The primary objective of this study is: • To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the dopamine receptor antagonist, risperidone. The secondary objectives of this study are: * To establish whether patients with schizophrenia are able to reliably complete the biomarker test battery and to assess whether their responses are similar to healthy volunteers treated with ketamine. * To establish a multi-site recruitment and assessment capacity based on shared Standard Operating Procedures across three study centres.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Ketamine

Keywords

NMDA receptor antagonismcognitive processeshealthy volunteersdopamine antagonistschizophreniaHealthy VolunteersSchizophrenia

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.